Bruijnincx, Pieter C. A. and Sadler, P. J. (2009) Controlling platinum, ruthenium, and osmium reactivity for anticancer drug design. Advances in Inorganic Chemistry, Vol.61 . pp. 1-62. doi:10.1016/S0898-8838(09)00201-3 ISSN 0898-8838.

PDF WRAP_Sadler_AdvInorgChem2009_61_1_MRC_revised.pdf - Requires a PDF viewer. Download (2547Kb)

Request Changes to record.

Abstract

The main task of the medicinal chemist is to design molecules that interact
specifically with derailed or degenerating processes in a diseased organism,
translating the available knowledge of pathobiochemical and physiological data into
chemically useful information and structures. Current knowledge of the biological
and chemical processes underlying diseases is vast and rapidly expanding. In
particular the unraveling of the genome in combination with, for instance, the rapid
development of structural biology has led to an explosion in available information and
identification of new targets for chemotherapy. The task of translating this wealth of
data into active and selective new drugs is an enormous, but realistic, challenge. It
requires knowledge from many different fields, including molecular biology,
chemistry, pharmacology, physiology, and medicine and as such requires a truly
interdisciplinary approach.
Ultimately, the goal is to design molecules that satisfy all the requirements for a
candidate drug to function therapeutically. Therapeutic activity can then be achieved
by an understanding of and control over structure and reactivity of the candidate drug
through molecular manipulation.

Item Type:	Journal Article
Subjects:	R Medicine > RM Therapeutics. Pharmacology
Divisions:	Faculty of Science, Engineering and Medicine > Science > Chemistry
Library of Congress Subject Headings (LCSH):	Antineoplastic agents, Platinum -- Therapeutic use, Ruthenium -- Therapeutic use, Osmium -- Therapeutic use
Journal or Publication Title:	Advances in Inorganic Chemistry
Publisher:	Elsevier
ISSN:	0898-8838
Official Date:	2009
Dates:	Date Event 2009 Published
Volume:	Vol.61
Page Range:	pp. 1-62
DOI:	10.1016/S0898-8838(09)00201-3
Status:	Peer Reviewed
Access rights to Published version:	Open Access (Creative Commons)
Funder:	Royal Society (Great Britain), Engineering and Physical Sciences Research Council (EPSRC), Biotechnology and Biological Sciences Research Council (Great Britain) (BBSRC), Nederlandse Organisatie voor Wetenschappelijk Onderzoek [Netherlands Organisation for Scientific Research] (NWO), Wellcome Trust (London, England), European Commission (EC), Scottish Enterprise (SE), Oncosense Ltd.

Data sourced from Thomson Reuters' Web of Knowledge

Request changes or add full text files to a record

Repository staff actions (login required)

View Item

Downloads